Please login to the form below

Not currently logged in
Email:
Password:

ruxolitinib

This page shows the latest ruxolitinib news and features for those working in and with pharma, biotech and healthcare.

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Inrebic (fedratinib) is the second JAK inhibitor to be approved for myelofibrosis since Incyte’s Jakafi (ruxolitinib) was cleared by the FDA in 2011, and the first new treatment for the

Latest news

More from news
Approximately 9 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics